⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2531786 | 0.80 | — | — | |
| SCHEMBL20108499 | 0.70 | — | — | |
| SCHEMBL18942790 | 0.67 | — | — | |
| SCHEMBL18753213 | 0.67 | — | — | |
| SCHEMBL5980928 | 0.66 | ACHE (0.39) | — | |
| SCHEMBL5978331 | 0.66 | ACHE (0.39) | — | |
| SCHEMBL13698996 | 0.65 | — | — | |
| SCHEMBL12166378 | 0.65 | — | — | |
| SCHEMBL5980853 | 0.65 | PTPN1 (0.33) | — | |
| SCHEMBL13699082 | 0.65 | PTPN1 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11254686-B1 | Compounds and methods for modulating adenosine A2B receptor and adenosine A2A receptor | CORVUS PHARMACEUTICALS, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| US-10961293-B2 | Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | JANSSEN PHARMACEUTICS NV (BE) | 2021-03-30 | — | — | US | disclosed |
| WO-2020255425-A1 | ANTI-HBV AGENT | 国立研究開発法人理化学研究所 | 2020-12-24 | — | — | WO | disclosed |
| US-20190345214-A1 | CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-11-14 | — | — | US | disclosed |
| EP-2691095-B1 | IMIDAZOLYL AMIDE COMPOUNDS AND USES RELATED THERETO | UNIV EMORY (US) | 2017-07-05 | — | — | EP | disclosed |
| EP-3135668-A1 | NOVEL DISUBSTITUTED 1, 2, 4-TRIAZINE COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2017-03-01 | — | — | EP | disclosed |
| WO-2015090603-A1 | FLUOROMETHYL-SUBSTITUTED PYRROLE CARBOXAMIDES III | Grünenthal GmbH (DE) | 2015-06-25 | — | — | WO | disclosed |
| EP-2299824-B1 | PYRAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH | MERCK SHARP & DOHME (US) | 2013-06-19 | — | — | EP | disclosed |
| EP-2325190-B1 | Composition for charge-transporting film and ion compound, charge-transporting film and organic electroluminescent device using same | MITSUBISHI CHEM CORP (JP) | 2013-05-08 | — | — | EP | disclosed |
| WO-2012169571-A1 | NOVEL N-(PYRIDIN-2-YL)ALKANAMIDE DERIVATIVE AND SHIP2 INHIBITOR CONTAINING SAME AS AN ACTIVE INGREDIENT | 国立大学法人 富山大学 (JP) | 2012-12-13 | — | — | WO | disclosed |
| US-20080090785-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| WO-2008021788-A2 | POLYAMINE COMPOUNDS | TAIGEN BIOTECHNOLOGY CO., LTD. (CN) | 2008-02-21 | — | — | WO | disclosed |
| EP-1500657-B1 | Substituted pyrazoles as P38 kinase inhibitors | SEARLE LLC (US) | 2007-09-19 | — | — | EP | disclosed |
| WO-2007100807-A2 | NPC1L1 ORTHOLOGUES | SCHERING CORPORATION (US) | 2007-09-07 | — | — | WO | disclosed |
| EP-1813606-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-08-01 | — | — | EP | disclosed |
| EP-1238970-B9 | CYCLOAMINE CCR5 RECEPTOR ANTAGONISTS | TEIJIN LTD (JP) | 2007-05-09 | — | — | EP | disclosed |
| WO-2007026097-A1 | NOVEL INDOLE COMPOUNDS | LABORATOIRES FOURNIER S.A. (FR) | 2007-03-08 | — | — | WO | disclosed |
| EP-1757610-A1 | CONDENSED PYRIMIDINE DERIVATIVE AND XANTHINE OXIDASE INHIBITOR | Nippon Chemiphar Co., Ltd. (JP) | 2007-02-28 | — | — | EP | disclosed |
| EP-1749817-A1 | NEUROGENIC PAIN CONTROL AGENT COMPOSITION | Maruishi Pharmaceutical Co., Ltd. (JP) | 2007-02-07 | — | — | EP | disclosed |
| US-20070010509-A1 | Cycloamine ccr5 receptor antagonists | TEIJIN PHARMA LIMITED (JP) | 2007-01-11 | — | — | US | disclosed |